119.79
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $119.79, with a volume of 9.94M.
It is up +1.14% in the last 24 hours and up +7.92% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$118.44
Open:
$116.06
24h Volume:
9.94M
Relative Volume:
1.46
Market Cap:
$148.64B
Revenue:
$29.04B
Net Income/Loss:
$8.11B
P/E Ratio:
18.56
EPS:
6.4525
Net Cash Flow:
$9.37B
1W Performance:
-0.95%
1M Performance:
+7.92%
6M Performance:
+12.44%
1Y Performance:
+34.87%
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
GILD
Gilead Sciences Inc
|
119.79 | 146.96B | 29.04B | 8.11B | 9.37B | 6.4525 |
|
LLY
Lilly Eli Co
|
862.86 | 757.06B | 59.42B | 18.41B | -50.20M | 20.22 |
|
JNJ
Johnson Johnson
|
188.87 | 455.48B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
218.04 | 403.13B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
123.79 | 235.26B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
85.98 | 215.51B | 63.99B | 19.05B | 14.72B | 7.5596 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
2,128 Shares in Gilead Sciences, Inc. $GILD Purchased by Elm Partners Management LLC - MarketBeat
Real time alert setup for Gilead Sciences Inc. performanceQuarterly Profit Report & Community Verified Watchlist Alerts - newser.com
What candlestick patterns are forming on Gilead Sciences Inc.Trade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Longbow Finance SA Purchases 9,390 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Syverson Strege & Co Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
NWK Group Inc. Has $7.33 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Assetmark Inc. - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2025 Earnings Call Transcript - Insider Monkey
Gilead Sciences, Inc. (GILD) Analyst insights, Price targets and Recommendations - Yahoo! Finance Australia
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $105.00 at Royal Bank Of Canada - MarketBeat
Gilead Sciences' (GILD) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Morgan Stanley Boosts Gilead Sciences (NASDAQ:GILD) Price Target to $147.00 - MarketBeat
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $145.00 - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Plans $0.79 Quarterly Dividend - MarketBeat
Gilead Sciences (NASDAQ:GILD) Given New $110.00 Price Target at The Goldman Sachs Group - MarketBeat
Gilead Sciences (NASDAQ:GILD) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Wells Fargo Maintains Gilead Sciences (GILD) Overweight Recommendation - Nasdaq
Fisher Funds Management LTD Reduces Position in Gilead Sciences, Inc. $GILD - MarketBeat
Atria Investments Inc Purchases 14,392 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Price momentum metrics for Gilead Sciences Inc. explainedTrade Analysis Report & Proven Capital Preservation Methods - newser.com
JP Morgan Raises Gilead Sciences (GILD) Price Target to $150 | G - GuruFocus
Gilead Sciences (NASDAQ:GILD) Posts Quarterly Earnings Results - MarketBeat
Gilead Sciences (GILD) Profit Margin Surge Reinforces Bullish Narratives on Operational Turnaround - Yahoo Finance
Needham Reiterates Gilead Sciences (GILD) Buy Recommendation - Nasdaq
Gilead Sciences (NASDAQ:GILD) Updates FY 2025 Earnings Guidance - MarketBeat
Gilead Stock Reverses; Why Its New HIV Shot Looks Better - Investor's Business Daily
Research Alert: CFRA Keeps Buy Rating On Shares Of Gilead Sciences, Inc. - 富途牛牛
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026 - Benzinga
RBC Capital Maintains Gilead Sciences (GILD) Rating, Raises Pric - GuruFocus
Gilead’s long-acting PrEP Yeztugo takes off while cell therapy declines continue to haunt sales - Fierce Pharma
Gilead Sciences: Strong Performance and Future Potential Drive Buy Rating - TipRanks
Gilead's Cell Therapy Portfolio Slumps in Q3, but Firm Still Optimistic About In Vivo Opportunities - Precision Medicine Online
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow - TradingView
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead - Enidnews.com
Does Gilead Sciences Offer Strong Value After Breakthroughs in Antiviral Treatments? - simplywall.st
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir) - BioSpace
Gilead GILD Q3 2025 Earnings Call Transcript - AOL.com
Gilead Sciences (GILD) Maintains Dividend, Adjusts 2025 Outlook - GuruFocus
Gilead Sciences (GILD) Acquires Key Assets from HOOKIPA Pharma - GuruFocus
Hookipa Pharma Completes Sales of HBV and HIV Assets to Gilead Sciences - MarketScreener
Gilead 3rd-qtr EPS beats expectations - The Pharma Letter
GILD Receives 'Buy' Rating Reiteration from Needham | GILD Stock News - GuruFocus
GILD Q3 Deep Dive: HIV and Liver Disease Strength Offset Oncology Headwinds - Yahoo Finance
Impact Partnership Wealth LLC Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
HOOKIPA Pharma Inc. Completes Asset Sale of HB-400 and HB-500 Programs to Gilead Sciences - Quiver Quantitative
Gilead Still Hungry for Deals as HIV Portfolio Grows, Veklury Crashes - BioSpace
Amalgamated Bank Buys 22,916 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Goldman Sachs Adjusts Price Target on Gilead Sciences to $110 From $108, Maintains Neutral Rating - MarketScreener
Morgan Stanley Adjusts Price Target on Gilead Sciences to $147 From $143, Maintains Overweight Rating - MarketScreener
Wells Fargo Adjusts Price Target on Gilead Sciences to $145 From $140, Maintains Overweight Rating - MarketScreener
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):